Supplemental Table 9. Univariate and multivariate linear regression analyses of the association between change in oxylipins and change in DAS28CRP after six months of biologic therapy.

Univariate Linear Regression	
	Total Cohort
6k PGF1α$^{\%}$ (N=48-54)	-8.4 (12.9)
TXB2$^{\%}$ (N=72-86)	0.9 (0.4)*
PGE2$^{\%}$ (N=57-66)	-1.7 (1.6)
LXA4$^{\%}$ (N=50-61)	-1.0 (2.1)
RvD1$^{\%}$ (N=82-93)	2.4 (10.2)
13,14-dihydro-15k PGF2α$^{\%}$ (N=82-93)	-6.7 (7.0)
6trans12epi LTB4 + LTB4$^{\%}$ (N=65-71)	-0.3 (0.7)
13HODE$^{\%}$ (N=82-93)	0.0 (0.3)
9HODE$^{\%}$ (N=82-93)	-0.1 (0.3)
15HETE$^{\%}$ (N=82-93)	0.3 (0.4)
14S-HDHA$^{\%}$ (14S-HDoHE) (N=82-91)	0.9 (0.5)
11HETE$^{\%}$ (N=82-93)	0.3 (0.4)
12HETE$^{\%}$ (N=82-93)	0.9 (0.2)*
5HETE$^{\%}$ (N=82-93)	0.1 (0.2)
5-oxoETE$^{\%}$ (N=82-93)	0.4 (0.6)
Multivariate Linear Regression	
	Total Cohort
TXB2$^{\%}$	0.05 (0.04)
BMI	0.05 (0.01)*
Seropositive	-0.0006 (0.12)
12HETE$^{\%}$	0.82 (0.22)*
BMI	0.05 (0.01)*
Seropositive	0.05 (0.11)

*p<0.05
Values are model coefficient estimate (SE)
%Values represented as $Log_{10}(x+1)*10^3$, and represent change over 6 months.